Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  De Nicola, Stella ^a   Dongiovanni, Paola ^a   Aghemo, Alessio ^a   Cheroni, Cristina ^b   D'Ambrosio, Roberta ^a,c   Pedrazzini, Michele ^c   Marabita, Francesco ^b,d   Donnici, Lorena ^b   Maggioni, Marco ^a   Fargion, Silvia ^a,c   Colombo, Massimo ^a,c   De Francesco, Raffaele ^b   Valenti, Luca ^a,c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Istituto Nazionale di Genetica Molecolare   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; FEMALE; FIBROSIS PROGRESSION RATE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HOMOZYGOSITY; HUMAN; LIPID METABOLISM; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PNPLA3 GENE; PROSPECTIVE STUDY; SCORING SYSTEM; ADOLESCENT; AGED; CHRONIC HEPATITIS C; COMPLICATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; MULTIVARIATE ANALYSIS; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; DISEASE PROGRESSION; FATTY LIVER; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; LIPASE; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84932117621     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106022     Document Type: Article

References (38)

1. Maasoumy B, Wedemeyer H (2012) Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26: 401-412.
2. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-832. (Pubitemid 27129209)
3. Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, et al. (2011) Genetic variation in the Interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 54: 1127-1134.
4. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, et al. (2006) Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130: 1636-1642.
5. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, et al. (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33: 1358-1364. (Pubitemid 32496971)
6. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, et al. (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31: 828-833. (Pubitemid 30169926)
7. Trepo E, Potthoff A, Pradat P, Bakshi R, Young B, et al. (2011) Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol 55: 38-44.
8. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40: 1461-1465.
9. Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, et al. (2012) Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 57: 1257-1262.
10. Hyysalo J, Gopalacharyulu P, Bian H, Hyotylainen T, Leivonen M, et al. (2013) Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity. Diabetes 63: 312-322.
11. Ruhanen H, Perttila JD, Holtta-Vuori MD, Zhou YD, Yki-Jarvinen HP, et al. (2014) PNPLA3 mediates hepatocyte triacylglycerol remodelling. J Lipid Res.
12. He S, McPhaul C, Li JZ, Garuti R, Kinch L, et al. (2010) A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285: 6706-6715.
13. Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, et al. (2012) Adiponutrin functions as a nutritionally regulated lysophosphatidic Acid acyltransferase. Cell Metab 15: 691-702.
14. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, et al. (2010) Homozygosity for the PNPLA3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51: 1209-1217.
15. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, et al. (2010) I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52: 1274-1280.
16. Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53: 1883-1894.
17. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA (2009) Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42: 21-23.
18. Stickel F, Buch S, Lau K, Zu Schwabedissen HM, Berg T, et al. (2011) Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 53: 86-95.
19. Burza MA, Molinaro A, Attilia ML, Rotondo C, Attilia F, et al. (2014) PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis. Liv Int 34: 514-520.
20. Valenti L, Aghemo A, Stattermayer AF, Maggioni P, De Nicola S, et al. (2012) Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther 35: 1434-1442.
21. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, et al. (2011) Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53: 791-799.
22. Muller T, Buch S, Berg T, Hampe J, Stickel F (2011) Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol 55: 732-733.
23. Trepo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, et al. (2011) Impact of PNPLA3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54: 60-69.
24. Trepo E, Nahon P, Bontempi G, Valenti L, Falleti E, et al. (2013) Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology.
25. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, et al. (2014) The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis. Am J Gastroenterol 109: 325-334.
26. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321. (Pubitemid 40770284)
28. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, et al. (2007) The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102: 2708-2715. (Pubitemid 350179336)
29. Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, et al. (2012) The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol 12: 111.
30. Reggiardo MV, Fay F, Tanno M, Garcia-Camacho G, Bottaso O, et al. (2012) Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects. Ann Hepatol 11: 658-666.
31. Knolle PA, Thimme R (2014) Hepatic Immune Regulation and its Involvement in Viral Hepatitis Infection. Gastroenterology.
32. Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL, et al. (2011) HCV and the hepatic lipid pathway as a potential treatment target. J Hepatol 55: 1428-1440.
33. Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, et al. (2013) PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 19: 6969-6978.
34. Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, et al. (2011) Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis. J Hepatol 55: 529-535.
35. Valenti L, Aghemo A, Stattermayer AF (2012) Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. J Hepatol 56: 1209-1210.
36. Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, et al. (2014) PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet.
37. Aghemo A, De Francesco R (2013) New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58: 428-438.
38. Rosselli M, MacNaughtan J, Jalan R, Pinzani M (2013) Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut 62: 1234-1241.